NewLink Genetics

NLNK NASDAQ
1.810
+0.120
+7.10%
After Hours: 1.810 0 0.00% 16:51 05/22 EDT
Open
1.690
Prev Close
1.690
High
1.830
Low
1.690
Volume
741.20K
Avg Vol (3M)
507.96K
52 Week High
5.61
52 Week Low
1.278
% Turnover
1.99%
Market Cap
67.47M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
MORE >

Recently

Name
Price
%Change